Helios Pharmaceutical Company Limit Pharmaceutical Import Profile — Vietnam (DGFT 2022–2026)

Name: Helios Pharmaceutical Company Limit Pharmaceutical Import Records from India — 2 Products, $474.8K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Helios Pharmaceutical Company Limit — Pharmaceutical Importer Profile (2026) | 2 Products, $474.8K Trade | TransData Nexus

Helios Pharmaceutical Company Limit

Pharmaceutical Importer · Vietnam · Advanced Oncology Focus · $474.8K Total Trade · DGFT Verified

Helios Pharmaceutical Company Limit is a pharmaceutical importer based in Vietnam with a total trade value of $474.8K across 2 products in 2 therapeutic categories. Based on 12 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Helios Pharmaceutical Company Limit sources from 5 verified Indian suppliers, with Naprod Life Sciences Private Limited accounting for 37.1% of imports.

Helios Pharmaceutical Company Limit — Import Portfolio & Supplier Network

Helios Pharmaceutical Company Limit import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Helios Pharmaceutical Company Limit?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Naprod Life Sciences Private Limited	$390.6K	9	37.1%
Cadila Pharmaceuticals Limited	$300.8K	10	28.6%
Gennova Biopharmaceuticals Limited	$282.0K

What Formulations Does Helios Pharmaceutical Company Limit Import?

Formulation	Value	Ships
Naprocap 500 (capecitabine tablets USP	$151.4K	4
Pharmaceuticals products ( finished product)-hamsyl 3750 IU INJ 1 vial(pegaspargase injection 3750 IU)	$90.8K	2
Pharma : hamsyl 3750 IU injection	$90.5K	2
Naprocap 500(capecitabine tablets	$89.1K	2
Pharma prod:rabeloc iv (raw	$50.0K	1
Naprocap 500 capecitabine tablets USP	$50.0K	1
Pharma product:rabeloc iv raw material:rabeprazole sodium 20mgbatch ay84e3017ay84e3018	$50.0K	1
Naprocap 500 (capecitabine tablets USP 500MG) (28647 bottelx10=286470 tabs)	$50.0K	1
Naprocap 500 (capecitabine tablets USP 500MG) (28672 bottelx10=286720 tabs)	$50.0K	1
Pha drg & med amdepin duo cont. amlodipine besilate & atorvastatin calcium	$50.0K	1
Rabeloc iv (r/m : rabeprazole sodium 20MG) batch ay84e5013 to ay84e5016 mfg dt-19/03/2025 exp	$50.0K	1
Pharmaceutical product rabeloc iv (raw material:rabeprazole sodium 20MG) batch ay845002a,ay845006a	$49.1K	1
Pharma : hamsyl injection	$45.4K	1
Hamsyl 3750 IU injection (pegaspargase injection 3750 IU/5ML) - 1 vial(inv. no.:2503200079 dt. 20.03.2025)	$45.1K	1
Pharmaceutical product rabeloc iv raw material rabeprazole sodium 20MG batch ay84e5012 mfg dt 19 03	$32.0K	1

Helios Pharmaceutical Company Limit imports 32 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Capecitabine	Advanced Oncology	$450.0K	9	0.5%	15
2	Vincristine	Oncology	$24.8K	3	1.2%	10

Helios Pharmaceutical Company Limit imports 2 pharmaceutical products across 2 categories into Vietnam totaling $474.8K.

Helios Pharmaceutical Company Limit — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Helios Pharmaceutical Company Limit is a pharmaceutical importer and buyer based in Vietnam, specializing in the acquisition of finished pharmaceutical formulations from India. The company has engaged in 12 shipments from India, with a total import value of $475,000 USD. These imports encompass two primary products across two therapeutic categories, indicating a focused portfolio. The top five products imported include Capecitabine, accounting for $450,000 USD (94.8% of total imports), and Vincristine, totaling $25,000 USD (5.2% of total imports). This concentration suggests that Helios Pharmaceutical Company Limit plays a significant role in the oncology segment within Vietnam's pharmaceutical market.

2Distribution Network

Specific details regarding Helios Pharmaceutical Company Limit's warehouse locations and logistics capabilities are not publicly available. However, given the company's substantial import activities, it is likely that they have established distribution networks within Vietnam to effectively manage the delivery of imported pharmaceutical products. The focus on oncology medications suggests a targeted distribution strategy aimed at healthcare facilities and pharmacies specializing in cancer treatment.

3Industry Role

Helios Pharmaceutical Company Limit functions primarily as a pharmaceutical importer and buyer, sourcing finished pharmaceutical formulations from Indian manufacturers. Their role is pivotal in introducing and distributing oncology medications within Vietnam, thereby contributing to the availability of specialized treatments in the local market. By focusing on high-demand oncology drugs, they address critical healthcare needs and support the healthcare infrastructure in Vietnam.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Helios Pharmaceutical Company Limit

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Helios Pharmaceutical Company Limit's sourcing strategy exhibits a high degree of concentration, with the top five products accounting for 100% of their imports. This indicates a strategic focus on specific oncology medications, particularly Capecitabine and Vincristine. While such concentration can lead to favorable terms with suppliers and streamlined operations, it also poses risks related to supply chain disruptions. The company's reliance on a limited number of products suggests a need for robust supplier relationships and contingency planning to mitigate potential supply chain challenges.

2Supply Chain Resilience

The resilience of Helios Pharmaceutical Company Limit's supply chain is closely tied to the stability and reliability of their Indian suppliers. With a portfolio concentrated on two primary products, the company is highly dependent on the uninterrupted supply of these medications. The absence of publicly available information on backup suppliers and the diversity of formulations imported indicates potential vulnerabilities. To enhance supply chain resilience, it would be prudent for the company to diversify its supplier base and establish contingency plans to address potential disruptions.

3Strategic Implications

Importing Pharmaceuticals into Vietnam — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Vietnam

1Regulatory Authority & Framework

In Vietnam, the pharmaceutical industry is regulated by the Ministry of Health, specifically the Drug Administration of Vietnam (DAV). The legal framework governing pharmaceutical imports includes the Law on Pharmacy No. 105/2016/QH13, which outlines the conditions for importing pharmaceutical products. Decree No. 54/2017/ND-CP provides detailed regulations on the implementation of the Law on Pharmacy, including procedures for drug registration and importation. These regulations ensure that imported pharmaceutical products meet the required safety, efficacy, and quality standards before entering the Vietnamese market.

2Import Licensing & GMP

To import pharmaceutical products into Vietnam, companies must obtain an import license from the Ministry of Health. This license is granted upon demonstrating compliance with Good Manufacturing Practice (GMP) standards. Vietnam recognizes GMP certificates from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must also ensure that their suppliers hold valid GMP certifications to guarantee the quality of the imported products.

3Quality & Labeling

Helios Pharmaceutical Company Limit — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Helios Pharmaceutical Company Limit's focus on importing oncology medications, particularly Capecitabine and Vincristine, aligns with the growing demand for cancer treatments in Vietnam. The high import value of these products indicates a strategic decision to address critical healthcare needs in the oncology sector. This product strategy is likely driven by the increasing prevalence of cancer in Vietnam and the need for effective treatment options.

2Sourcing Profile

Helios Pharmaceutical Company Limit's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular emphasis on oncology medications. The company's portfolio is highly concentrated, focusing on a limited number of products from a select group of suppliers. This approach suggests a strategic choice to specialize in specific therapeutic areas and maintain strong relationships with key suppliers.

3Market Positioning

Based on its product mix, Helios Pharmaceutical Company Limit serves the hospital and specialized oncology treatment segments of the Vietnamese market. By focusing on high-demand oncology drugs, the company positions itself as a key supplier of essential cancer treatments, catering to healthcare facilities and pharmacies that provide specialized care.

Seller's Guide — How to Become a Supplier to Helios Pharmaceutical Company Limit

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Helios Pharmaceutical Company Limit, given the company's focused product portfolio and reliance on specific oncology medications. Suppliers offering high-quality, GMP-compliant formulations in the oncology category could meet the company's sourcing needs. However, potential suppliers should be prepared to meet stringent regulatory requirements and quality standards to establish a successful partnership.

2Requirements & Qualifications

Indian exporters seeking to supply Helios Pharmaceutical Company Limit must ensure that their products are registered with the Drug Administration of Vietnam and hold valid Market Authorization. Suppliers must possess GMP certifications recognized by international bodies such as WHO or PIC/S. Additionally, compliance with Vietnamese labeling requirements, including providing labels in Vietnamese with usage instructions, is essential.

3How to Approach

Frequently Asked Questions — Helios Pharmaceutical Company Limit

What products does Helios Pharmaceutical Company Limit import from India?

Helios Pharmaceutical Company Limit imports 2 pharmaceutical products across 2 categories. Top imports: Capecitabine ($450.0K), Vincristine ($24.8K).

Who supplies pharmaceuticals to Helios Pharmaceutical Company Limit from India?

Helios Pharmaceutical Company Limit sources from 5 verified Indian suppliers. The primary supplier is Naprod Life Sciences Private Limited (37.1% of imports, $390.6K).

What is Helios Pharmaceutical Company Limit's total pharmaceutical import value?

Helios Pharmaceutical Company Limit's total pharmaceutical import value from India is $474.8K, based on 12 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Helios Pharmaceutical Company Limit focus on?

Helios Pharmaceutical Company Limit imports across 2 categories. The largest: Advanced Oncology (94.8%), Oncology (5.2%).

Get Full Helios Pharmaceutical Company Limit Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.